|
Current issue
Archive
Online First
About the journal
Editorial board
Abstracting and indexing
Subscription
Contact
Ethical standards and procedures
Special Issues
Instructions for authors
Publication charge
Editorial System
Submit your Manuscript
Open access 
|
4/2011
vol. 10 abstract:
Review paper
Ultra low dose oral menopausal hormone therapy – unrealized dream or reality?
Grzegorz Stachowiak
,
Tomasz Pertyński
Przegląd Menopauzalny 2011; 4: 271–274
Online publish date: 2011/08/30
View
full text
Get citation
ENW EndNote
BIB JabRef, Mendeley
RIS Papers, Reference Manager, RefWorks, Zotero
AMA
APA
Chicago
Harvard
MLA
Vancouver
Reduction of estrogen and progestogen doses is one of the main trends in oral menopausal hormone therapy (MHT). Studies on ultra low oral MHT, composed of 0,5 mg estradiol plus reduced doses of various progestoagens (e.g. norethisterone acetate, dydrogesterone), revealed both its high safety profile as well as therapeutic efficacy in alleviating of numerous aliments of the menopausal period.
keywords:
hormone therapy, ultra low doses, menopause, norethisterone acetate, dydrogesterone |
 |
